Pfenex, Hospira to develop and commercialize proposed biosimilar of Lucentis
PF582 is Pfenex’s biosimilar candidate to Genentech’s Lucentis (ranibizumab injection). As part of the deal, Pfenex will receive an upfront payment of $51m once the collaboration receives antitrust
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.